

Appendix B. Table of Contents

APPENDIX B. Supplemental Analyses

1. **Supplement to Table 7a.** (pp. 2,3)
Distribution of covariates for all sites by study CHCs in new users for ages 10-34 years and ages 35-55 years
2. **Supplement to Table 9.** (p.4)
Incidence rates for subgroups of main study endpoints (new users)
3. **Supplement to Tables 10a-d.** (pp 4-7)
Age-specific incidence rates and age-adjusted rates for comparators (except LNG2) for ATE, VTE, CVD mortality, and total mortality
4. **Supplement to Table 12b.** (p.8)
Relative hazard of subgroups of main study endpoints associated with study exposure CHCs relative to the combined comparator CHCs group (new users)

Appendix B. Supplemental Analyses

Table 7aS1.

| Distribution of covariates for all sites by study CHCs in NEW users Ages 10-34 | | | | | | | | | | | |
|--|-------|-------|---|------|-------|---|-------|-------|---|-------------|-------|
| COVARIATE | DRSP | | | ETON | | | NGNM | | | Comparators | |
| | n | % | p | n | % | p | N | % | p | n | % |
| ACE_INHIBITORS | 460 | 0.49 | * | 93 | 0.56 | * | 243 | 0.42 | ‡ | 1583 | 0.53 |
| ACNE | 4300 | 4.61 | ‡ | 147 | 0.88 | ‡ | 401 | 0.70 | ‡ | 7539 | 2.54 |
| ADRENAL_INSUFFICIENCY | 1 | 0.00 | ■ | 2 | 0.01 | * | 3 | 0.01 | * | 19 | 0.01 |
| AMPHETAMINE_DEPENDENCY | 142 | 0.15 | * | 32 | 0.19 | * | 125 | 0.22 | ‡ | 415 | 0.14 |
| ANTICOAGULANTS | 0 | 0.00 | - | 0 | 0.00 | - | 0 | 0.00 | 0 | 2 | 0.00 |
| ASTHMA | 2784 | 2.98 | ‡ | 564 | 3.37 | ‡ | 1783 | 3.11 | ‡ | 8228 | 2.77 |
| ATRIAL_FIBRILLATION | 7 | 0.01 | * | 4 | 0.02 | ■ | 5 | 0.01 | † | 22 | 0.01 |
| BETA_BLOCKERS | 1032 | 1.11 | * | 209 | 1.25 | * | 634 | 1.11 | * | 3509 | 1.18 |
| CHRONIC_KIDNEY_DISEASE | 3 | 0.00 | * | 1 | 0.01 | * | 8 | 0.01 | ■ | 14 | 0.00 |
| COAGULOPATHY | 47 | 0.05 | * | 15 | 0.09 | * | 40 | 0.07 | * | 163 | 0.05 |
| COCAINE_DEPENDENCY | 86 | 0.09 | * | 19 | 0.11 | * | 71 | 0.12 | ‡ | 229 | 0.08 |
| COPD | 111 | 0.12 | ‡ | 44 | 0.26 | * | 203 | 0.35 | ‡ | 655 | 0.22 |
| DIABETES | 1624 | 1.74 | ‡ | 276 | 1.65 | * | 954 | 1.67 | † | 4399 | 1.48 |
| DIURETIC_POTASSIUM_SPARIN | 660 | 0.71 | ‡ | 62 | 0.37 | * | 183 | 0.32 | † | 1212 | 0.41 |
| DYSMENORRHEA | 750 | 0.80 | ■ | 71 | 0.42 | ‡ | 349 | 0.61 | ‡ | 2649 | 0.89 |
| EPILEPSY | 120 | 0.13 | † | 22 | 0.13 | * | 129 | 0.23 | † | 505 | 0.17 |
| HEART_FAILURE | 15 | 0.02 | ■ | 15 | 0.09 | ‡ | 26 | 0.05 | ■ | 86 | 0.03 |
| HEPATIC_DYSFUNCTION | 43 | 0.05 | * | 18 | 0.11 | ‡ | 46 | 0.08 | ‡ | 130 | 0.04 |
| HRT | 3037 | 3.26 | ‡ | 745 | 4.45 | ■ | 3556 | 6.21 | ‡ | 12053 | 4.06 |
| HYPERLIPIDEMIA | 980 | 1.05 | ■ | 159 | 0.95 | * | 566 | 0.99 | * | 2846 | 0.96 |
| HYPERTENSION | 1389 | 1.49 | ‡ | 322 | 1.92 | † | 880 | 1.54 | * | 4886 | 1.65 |
| LUPUS | 29 | 0.03 | * | 14 | 0.08 | † | 31 | 0.05 | * | 111 | 0.04 |
| MIGRAINE | 1666 | 1.79 | * | 404 | 2.41 | ‡ | 1212 | 2.12 | ‡ | 5244 | 1.77 |
| NSAIDS | 15694 | 16.83 | ‡ | 2780 | 16.61 | ‡ | 11330 | 19.78 | ‡ | 53515 | 18.03 |
| OTHER_CARDIAC_DYSRHYTHMIA | 156 | 0.17 | ■ | 51 | 0.30 | † | 156 | 0.27 | † | 603 | 0.20 |
| OTHER_ISCHEMIC_HEART_DISE | 41 | 0.04 | * | 13 | 0.08 | * | 57 | 0.10 | ‡ | 163 | 0.05 |
| PERIPHERAL_VASCULAR_DISEA | 28 | 0.03 | ■ | 11 | 0.07 | * | 260 | 0.05 | * | 137 | 0.05 |
| PLATLET_INHIBITORS | 3 | 0.00 | * | 1 | 0.01 | * | 6 | 0.01 | * | 18 | 0.01 |
| POLYCYSTIC_OVARY_SYNDROM | 4 | 0.00 | ■ | 3 | 0.02 | * | 24 | 0.04 | ‡ | 43 | 0.01 |
| POTASSIUM | 116 | 0.12 | † | 26 | 0.16 | * | 114 | 0.20 | * | 497 | 0.17 |
| PREMENSTRUAL_TENSION_SYN | 112 | 0.12 | ‡ | 10 | 0.06 | * | 24 | 0.04 | * | 169 | 0.06 |
| RENAL_INSUFFICIENCY | 10 | 0.01 | * | 2 | 0.01 | * | 12 | 0.02 | * | 44 | 0.01 |
| STATINS | 327 | 0.35 | * | 48 | 0.29 | * | 146 | 0.25 | † | 1001 | 0.34 |
| SURGERY_INJURY | 631 | 0.68 | ‡ | 122 | 0.73 | * | 572 | 1.00 | ‡ | 2353 | 0.79 |
| THYROID | 126 | 0.14 | † | 32 | 0.19 | * | 122 | 0.21 | * | 554 | 0.19 |
| TIA | 0 | 0.00 | - | 2 | 0.01 | * | 1 | 0.00 | * | 16 | 0.01 |
| VARICOSE_VEINS | 75 | 0.08 | * | 13 | 0.08 | * | 39 | 0.39 | * | 199 | 0.07 |
| WARFARIN | 15 | 0.02 | * | 4 | 0.02 | * | 11 | 0.02 | * | 64 | 0.02 |

p-value of chi-square test for percentage of covariate for exposure CHC with percentage of covariate for comparator group:

* p-value >0.05 ■ = p-value <0.05 † = p-value <0.01 ‡ = p-value <0.001

Percent refers to number of women

Appendix B. Supplemental Analyses

Table S7a2.

| Distribution of covariates for all sites by study CHCs in NEW users Ages 35-55 | | | | | | | | | | | |
|--|------|-------|---|------|-------|---|------|-------|---|-------------|-------|
| COVARIATE | DRSP | | | ETON | | | NGNM | | | Comparators | |
| | n | % | p | n | % | p | N | % | p | n | % |
| ACE_INHIBITORS | 467 | 0.49 | ‡ | 92 | 3.83 | * | 175 | 3.48 | † | 1583 | 0.53 |
| ACNE | 306 | 1.94 | ‡ | 10 | 0.42 | ■ | 19 | 0.38 | † | 664 | 0.77 |
| ADRENAL_INSUFFICIENCY | 2 | 0.01 | * | 0 | 0.00 | - | 2 | 0.04 | * | 10 | 0.01 |
| AMPHETAMINE_DEPENDENCY | 14 | 0.09 | * | 5 | 0.21 | * | 8 | 0.16 | * | 78 | 0.09 |
| ANTICOAGULANTS | 0 | 0.00 | - | 0 | 0.00 | - | 0 | 0.00 | - | 1 | 0.00 |
| ASTHMA | 489 | 3.10 | * | 78 | 3.25 | * | 147 | 2.92 | * | 2696 | 3.12 |
| ATRIAL_FIBRILLATION | 4 | 0.03 | * | 2 | 0.08 | * | 0 | 0.00 | - | 41 | 0.05 |
| BETA_BLOCKERS | 607 | 3.84 | ‡ | 105 | 4.37 | * | 200 | 3.97 | ‡ | 4543 | 5.26 |
| CHRONIC_KIDNEY_DISEASE | 0 | 0.00 | - | 0 | 00.0 | - | 0 | 00.0 | - | 4 | 0.00 |
| COAGULOPATHY | 4 | 0.03 | * | 2 | 0.08 | * | 6 | 0.12 | † | 34 | 0.04 |
| COCAINE_DEPENDENCY | 14 | 0.09 | * | 2 | 0.08 | * | 7 | 0.14 | ■ | 54 | 0.06 |
| COPD | 59 | 0.37 | * | 22 | 0.92 | ‡ | 60 | 1.19 | ‡ | 342 | 0.40 |
| DIABETES | 530 | 3.36 | ■ | 111 | 4.62 | ■ | 291 | 5.78 | ‡ | 3222 | 3.73 |
| DIURETIC_POTASSIUM_SPARIN | 313 | 1.98 | * | 23 | 0.96 | ‡ | 86 | 1.71 | ■ | 1868 | 2.16 |
| DYSMENORRHEA | 174 | 1.10 | * | 20 | 0.83 | * | 32 | 0.64 | † | 955 | 1.11 |
| EPILEPSY | 23 | 0.15 | * | 5 | 0.21 | * | 13 | 0.26 | ■ | 114 | 0.13 |
| HEART_FAILURE | 3 | 0.02 | * | 3 | 0.12 | * | 7 | 0.14 | ■ | 44 | 0.05 |
| HEPATIC_DYSFUNCTION | 27 | 0.17 | 3 | 4 | 0.17 | * | 12 | 0.24 | † | 83 | 0.10 |
| HRT | 915 | 5.79 | ‡ | 94 | 3.92 | ‡ | 282 | 5.60 | ‡ | 8336 | 9.65 |
| HYPERLIPIDEMIA | 909 | 5.75 | ‡ | 169 | 7.04 | * | 368 | 7.31 | * | 5904 | 6.84 |
| HYPERTENSION | 1236 | 7.82 | ‡ | 235 | 9.79 | * | 488 | 9.69 | † | 9449 | 10.94 |
| LUPUS | 14 | 0.09 | * | 4 | 0.17 | * | 11 | 0.22 | ‡ | 62 | 0.07 |
| MIGRAINE | 451 | 2.86 | ■ | 74 | 3.08 | * | 116 | 2.30 | * | 2179 | 2.52 |
| NSAIDS | 4058 | 25.69 | ‡ | 527 | 21.95 | ‡ | 1327 | 26.36 | † | 24513 | 28.39 |
| OTHER_CARDIAC_DYSRHYTHMIA | 68 | 0.43 | ■ | 10 | 0.42 | * | 15 | 0.30 | * | 277 | 0.32 |
| OTHER_ISCHEMIC_HEART_DISE | 45 | 0.28 | * | 8 | 0.33 | * | 28 | 0.56 | ‡ | 249 | 0.29 |
| PERIPHERAL_VASCULAR_DISEA | 11 | 0.07 | * | 4 | 0.17 | * | 11 | 0.22 | † | 79 | 0.09 |
| PLATLET_INHIBITORS | 5 | 0.03 | * | 2 | 0.08 | * | 11 | 0.22 | ‡ | 57 | 0.07 |
| POLYCYSTIC_OVARY_SYNDROM | 1 | 0.01 | * | 0 | 00.0 | - | 3 | 0.06 | † | 9 | 0.01 |
| POTASSIUM | 119 | 0.75 | ‡ | 20 | 0.83 | * | 59 | 1.17 | * | 902 | 1.04 |
| PREMENSTRUAL_TENSION_SYN | 105 | 0.66 | ‡ | 6 | 0.25 | * | 2 | 0.04 | † | 248 | 0.29 |
| RENAL_INSUFFICIENCY | 2 | 0.01 | * | 0 | 00.0 | - | 0 | 00.0 | - | 20 | 0.02 |
| STATINS | 436 | 2.76 | ‡ | 75 | 3.12 | * | 169 | 3.36 | * | 3064 | 3.55 |
| SURGERY_INJURY | 369 | 2.34 | ‡ | 31 | 1.29 | ‡ | 108 | 2.15 | ‡ | 2551 | 2.95 |
| THYROID | 36 | 0.23 | ■ | 8 | 0.33 | * | 9 | 0.18 | * | 295 | 0.34 |
| TIA | 1 | 0.01 | * | 2 | 0.08 | * | 0 | 00.0 | - | 31 | 0.04 |
| VARICOSE_VEINS | 62 | 0.39 | * | 12 | 0.50 | * | 11 | 0.22 | * | 286 | 0.33 |
| WARFARIN | 13 | 0.08 | * | 3 | 0.12 | * | 2 | 0.04 | * | 85 | 0.10 |

p-value of chi-square test for percentage of covariate for exposure CHC with percentage of covariate for comparator group:

* p-value >0.05 ■ = p-value <0.05 † = p-value <0.01 ‡ p-value <0.001

Percent refers to number of women

Appendix B. Supplemental Analyses

Table S9.

Incidence rates for all study outcomes (new users)

| Endpoint | Events | Rate (per 10K person-years) |
|------------------|--------|-----------------------------|
| AMI | 28 | 0.76 |
| Ischemic Stroke | 37 | 1.01 |
| All DVT | 204 | 5.56 |
| Hospitalized DVT | 90 | 2.45 |
| PE | 139 | 3.79 |

All denominators are 367,124 person-years.

Table S10a.

Age-specific incidence rates and age-adjusted rates for COMPARATORS (except LNG2) for ATE

| EXPOSURE | | Age-specific incidence rates | | | | | | | |
|----------|-----------|------------------------------|--------|----------------|--------------|-----------|--------|----------------|--------------|
| | | NEW USERS | | | | ALL USERS | | | |
| | | WY | Events | Rate (per 10K) | Age-Adj Rate | WY | Events | Rate (Per 10K) | Age-Adj Rate |
| LNG1 | Age (yrs) | | | | | | | | |
| | 10-14 | 896 | 0 | 0.00 | 1.48 | 1188 | 0 | 0.00 | 0.82 |
| | 15-19 | 4706 | 0 | 0.00 | | 8234 | 0 | 0.00 | |
| | 20-24 | 3337 | 1 | 3.00 | | 7477 | 1 | 1.34 | |
| | 25-29 | 2412 | 0 | 0.00 | | 5457 | 0 | 0.00 | |
| | 30-34 | 1502 | 2 | 13.32 | | 3543 | 4 | 11.29 | |
| | 35-39 | 997 | 0 | 0.00 | | 2372 | 0 | 0.00 | |
| | 40-44 | 782 | 2 | 25.59 | | 1718 | 2 | 11.64 | |
| | 45-49 | 617 | 2 | 32.44 | | 1346 | 2 | 14.86 | |
| | 50-55 | 203 | 0 | 0.00 | | 448 | 0 | 0.00 | |
| | 15452 | 7 | | | | 31783 | 9 | | |
| NETA | Age (yrs) | | | | 2.18 | | | | 1.73 |
| | 10-14 | 510 | 0 | 0.00 | | 670 | 0 | 0.00 | |
| | 15-19 | 5847 | 0 | 0.00 | | 10402 | 1 | 0.96 | |
| | 20-24 | 8992 | 1 | 1.11 | | 20798 | 2 | 0.96 | |
| | 25-29 | 9186 | 1 | 1.09 | | 22675 | 3 | 1.32 | |
| | 30-34 | 7294 | 1 | 1.37 | | 19190 | 2 | 1.04 | |
| | 35-39 | 7310 | 3 | 4.10 | | 18177 | 3 | 1.65 | |
| | 40-44 | 10818 | 4 | 3.70 | | 25608 | 7 | 2.73 | |
| | 45-49 | 12441 | 4 | 3.22 | | 30210 | 16 | 5.30 | |
| | 50-55 | 4630 | 4 | 8.64 | | 13312 | 9 | 6.76 | |
| | 67028 | 18 | | | 161042 | 43 | | | |
| NGM | Age (yrs) | | | | 0.47 | | | | 0.94 |
| | 10-14 | 1640 | 0 | 0.00 | | 2235 | 0 | 0.00 | |
| | 15-19 | 18703 | 1 | 0.53 | | 36522 | 1 | 0.27 | |
| | 20-24 | 19077 | 0 | 0.00 | | 50638 | 0 | 0.00 | |
| | 25-29 | 15124 | 1 | 0.66 | | 42696 | 4 | 0.94 | |
| | 30-34 | 7832 | 0 | 0.00 | | 25350 | 0 | 0.00 | |
| | 35-39 | 3602 | 1 | 2.78 | | 13012 | 4 | 3.07 | |
| | 40-44 | 1579 | 0 | 0.00 | | 6255 | 1 | 1.60 | |
| | 45-49 | 634 | 0 | 0.00 | | 2625 | 2 | 7.62 | |
| | 50-55 | 107 | 0 | 0.00 | | 503 | 0 | 0.00 | |
| | 68298 | 3 | | | 179836 | 12 | | | |

ATE

Appendix B. Supplemental Analyses

Table S10b.

Age-specific incidence rates and age-adjusted rates for COMPARATORS (except LNG2) for VTE

| EXPOSURE | | Age-specific incidence rates | | | | | | | |
|----------|-----------|------------------------------|--------|----------------|--------------|-----------|--------|----------------|--------------|
| | | NEW USERS | | | | ALL USERS | | | |
| | | WY | Events | Rate (per 10K) | Age-Adj Rate | WY | Events | Rate (Per 10K) | Age-Adj Rate |
| LNG1 | Age (yrs) | | | | | | | | |
| | 10-14 | 896 | 0 | 0.00 | 1.75 | 1188 | 0 | 0.00 | 1.57 |
| | 15-19 | 4706 | 1 | 2.13 | | 8234 | 3 | 3.64 | |
| | 20-24 | 3337 | 1 | 3.00 | | 7477 | 3 | 4.01 | |
| | 25-29 | 2412 | 1 | 4.15 | | 5457 | 2 | 3.67 | |
| | 30-34 | 1502 | 1 | 6.66 | | 3543 | 1 | 2.82 | |
| | 35-39 | 997 | 0 | 0.00 | | 2372 | 0 | 0.00 | |
| | 40-44 | 782 | 5 | 63.97 | | 1718 | 6 | 34.93 | |
| | 45-49 | 617 | 2 | 32.44 | | 1346 | 2 | 14.86 | |
| | 50-55 | 203 | 0 | 0.00 | | 448 | 1 | 22.31 | |
| | 15452 | 11 | | | | 31783 | 18 | | |
| NETA | Age (yrs) | | | | | | | | |
| | 10-14 | 510 | 0 | 0.00 | 10.04 | 670 | 0 | 0.00 | 6.43 |
| | 15-19 | 5847 | 2 | 3.42 | | 10402 | 3 | 2.88 | |
| | 20-24 | 8992 | 1 | 1.11 | | 20798 | 4 | 1.92 | |
| | 25-29 | 9186 | 4 | 4.35 | | 22675 | 6 | 2.65 | |
| | 30-34 | 7294 | 5 | 6.85 | | 19190 | 8 | 4.17 | |
| | 35-39 | 7310 | 8 | 10.94 | | 18177 | 13 | 7.15 | |
| | 40-44 | 10818 | 22 | 20.34 | | 25608 | 30 | 11.71 | |
| | 45-49 | 12441 | 24 | 19.29 | | 30210 | 42 | 13.90 | |
| | 50-55 | 4630 | 12 | 25.92 | | 13312 | 29 | 21.79 | |
| | 67028 | 78 | | | | 161042 | 135 | | |
| NGM | Age (yrs) | | | | | | | | |
| | 10-14 | 1640 | 0 | 0.00 | 1.75 | 2235 | 0 | 0.00 | 4.41 |
| | 15-19 | 18703 | 3 | 1.60 | | 36522 | 8 | 2.19 | |
| | 20-24 | 19077 | 14 | 7.34 | | 50638 | 21 | 4.15 | |
| | 25-29 | 15124 | 8 | 5.29 | | 42696 | 20 | 4.68 | |
| | 30-34 | 7832 | 5 | 6.38 | | 25350 | 10 | 3.94 | |
| | 35-39 | 3602 | 11 | 30.54 | | 13012 | 14 | 10.76 | |
| | 40-44 | 1579 | 0 | 0.00 | | 6255 | 1 | 1.60 | |
| | 45-49 | 634 | 1 | 15.78 | | 2625 | 1 | 3.81 | |
| | 50-55 | 107 | 0 | 0.00 | | 503 | 0 | 0.00 | |
| | 68298 | 42 | | | | 179836 | 75 | | |

VTE

Appendix B. Supplemental Analyses

Table S10c.

Age-specific incidence rates and age-adjusted rates for COMPARATORS (except LNG2) for CVD Mortality

| EXPOSURE | | Age-specific incidence rates | | | | | | | |
|----------|-----------|------------------------------|--------|----------------|--------------|-----------|--------|----------------|--------------|
| | | NEW USERS | | | | ALL USERS | | | |
| | | WY | Events | Rate (per 10K) | Age-Adj Rate | WY | Events | Rate (Per 10K) | Age-Adj Rate |
| LNG1 | Age (yrs) | | | | | | | | |
| | 10-14 | 896 | 0 | 0.00 | 1.04 | 1188 | 0 | 0.00 | 0.54 |
| | 15-19 | 4706 | 0 | 0.00 | | 8234 | 0 | 0.00 | |
| | 20-24 | 3337 | 0 | 0.00 | | 7477 | 0 | 0.00 | |
| | 25-29 | 2412 | 1 | 4.15 | | 5457 | 1 | 1.83 | |
| | 30-34 | 1502 | 2 | 13.32 | | 3543 | 3 | 8.47 | |
| | 35-39 | 997 | 0 | 0.00 | | 2372 | 0 | 0.00 | |
| | 40-44 | 782 | 0 | 0.00 | | 1718 | 1 | 5.82 | |
| | 45-49 | 617 | 0 | 0.00 | | 1346 | 0 | 0.00 | |
| | 50-55 | 203 | 1 | 49.17 | | 448 | 1 | 22.31 | |
| | 15452 | 4 | | | | 31783 | 6 | | |
| NETA | Age (yrs) | | | | 0.27 | | | | 0.77 |
| | 10-14 | 510 | 0 | 0.00 | | 670 | 0 | 0.00 | |
| | 15-19 | 5847 | 1 | 1.71 | | 10402 | 1 | 0.96 | |
| | 20-24 | 8992 | 0 | 0.00 | | 20798 | 0 | 0.00 | |
| | 25-29 | 9186 | 0 | 0.00 | | 22675 | 1 | 0.44 | |
| | 30-34 | 7294 | 0 | 0.00 | | 19190 | 0 | 0.00 | |
| | 35-39 | 7310 | 0 | 0.00 | | 18177 | 2 | 1.10 | |
| | 40-44 | 10818 | 1 | 0.92 | | 25608 | 2 | 0.78 | |
| | 45-49 | 12441 | 0 | 0.00 | | 30210 | 2 | 0.66 | |
| | 50-55 | 4630 | 0 | 0.00 | | 13312 | 2 | 1.50 | |
| | 67028 | 2 | | | 161042 | 10 | | | |
| NGM | Age (yrs) | | | | 6.92 | | | | 0.37 |
| | 10-14 | 1640 | 0 | 0.00 | | 2235 | 0 | 0.00 | |
| | 15-19 | 18703 | 0 | 0.00 | | 36522 | 0 | 0.00 | |
| | 20-24 | 19077 | 0 | 0.00 | | 50638 | 3 | 0.59 | |
| | 25-29 | 15124 | 0 | 0.00 | | 42696 | 1 | 0.23 | |
| | 30-34 | 7832 | 1 | 1.28 | | 25350 | 2 | 0.79 | |
| | 35-39 | 3602 | 0 | 0.00 | | 13012 | 0 | 0.00 | |
| | 40-44 | 1579 | 0 | 0.00 | | 6255 | 0 | 0.00 | |
| | 45-49 | 634 | 0 | 0.00 | | 2625 | 0 | 0.00 | |
| | 50-55 | 107 | 0 | 0.00 | | 503 | 0 | 0.00 | |
| | 68298 | 1 | | | 179836 | 6 | | | |

CVD

Appendix B. Supplemental Analyses

Table S10d.

Age-specific incidence rates and age-adjusted rates for COMPARATORS (except LNG2) for Total Mortality

| EXPOSURE | | Age-specific incidence rates | | | | | | | |
|----------|-----------|------------------------------|--------|----------------|--------------|-----------|--------|----------------|--------------|
| | | NEW USERS | | | | ALL USERS | | | |
| | | WY | Events | Rate (per 10K) | Age-Adj Rate | WY | Events | Rate (Per 10K) | Age-Adj Rate |
| LNG1 | Age (yrs) | | | | | | | | |
| | 10-14 | 896 | 1 | 11.16 | 1.90 | 1188 | 1 | 8.42 | 4.30 |
| | 15-19 | 4706 | 0 | 0.00 | | 8234 | 1 | 1.21 | |
| | 20-24 | 3337 | 1 | 3.00 | | 7477 | 4 | 5.35 | |
| | 25-29 | 2412 | 1 | 4.15 | | 5457 | 1 | 1.83 | |
| | 30-34 | 1502 | 3 | 19.98 | | 3543 | 6 | 16.93 | |
| | 35-39 | 997 | 0 | 0.00 | | 2372 | 2 | 8.43 | |
| | 40-44 | 782 | 2 | 25.59 | | 1718 | 3 | 17.46 | |
| | 45-49 | 617 | 1 | 16.22 | | 1346 | 1 | 7.43 | |
| | 50-55 | 203 | 1 | 49.15 | | 448 | 2 | 44.63 | |
| | 15452 | 10 | | | | 31783 | 21 | | |
| NETA | Age (yrs) | | | | 1.18 | | | | 4.64 |
| | 10-14 | 510 | 0 | 0.00 | | 670 | 0 | 0.00 | |
| | 15-19 | 5847 | 1 | 1.71 | | 10402 | 3 | 2.88 | |
| | 20-24 | 8992 | 1 | 1.11 | | 20798 | 6 | 2.88 | |
| | 25-29 | 9186 | 2 | 2.18 | | 22675 | 3 | 1.32 | |
| | 30-34 | 7294 | 0 | 0.00 | | 19190 | 1 | 0.52 | |
| | 35-39 | 7310 | 2 | 2.74 | | 18177 | 7 | 3.85 | |
| | 40-44 | 10818 | 2 | 1.85 | | 25608 | 5 | 1.95 | |
| | 45-49 | 12441 | 2 | 1.61 | | 30210 | 5 | 1.66 | |
| | 50-55 | 4630 | 0 | 0.00 | | 147730 | 30 | 3.76 | |
| | 67028 | 10 | | | 295460 | 60 | | | |
| NGM | Age (yrs) | | | | 2.31 | | | | 3.20 |
| | 10-14 | 1640 | 0 | 0.00 | | 2235 | 0 | 0.00 | |
| | 15-19 | 18703 | 6 | 3.21 | | 36522 | 9 | 2.46 | |
| | 20-24 | 19077 | 4 | 2.10 | | 50638 | 16 | 3.16 | |
| | 25-29 | 15124 | 6 | 3.97 | | 42696 | 17 | 3.98 | |
| | 30-34 | 7832 | 2 | 2.55 | | 25350 | 8 | 3.16 | |
| | 35-39 | 3602 | 0 | 0.00 | | 13012 | 2 | 1.54 | |
| | 40-44 | 1579 | 0 | 0.00 | | 6255 | 1 | 1.60 | |
| | 45-49 | 634 | 0 | 0.00 | | 2625 | 2 | 7.62 | |
| | 50-55 | 107 | 0 | 0.00 | | 503 | 0 | 0.00 | |
| | 68298 | 18 | | | 179836 | 55 | | 179836 | |

TM

Appendix B. Supplemental Analyses

Table 12b suppl.

Relative hazard of study endpoints associated with study exposure CHCs relative to the combined comparator CHCs group (new users)

| All users | AMI | Ischemic stroke | DVT all | DVT hospitalized | PE |
|-----------|--------------------|-------------------|--------------------------|-------------------|--------------------------|
| DRSP | 2.02 (0.71, 5.77) | 1.96 (0.87, 4.40) | 1.58 (1.09, 2.28) | 1.74 (1.00, 3.02) | 2.22 (1.41, 3.36) |
| NGNM | 1.43 (0.29, 7.06) | 0.88 (0.19, 4.09) | 1.34 (0.80, 2.24) | 0.92 (0.37, 2.27) | 1.71 (0.93, 3.12) |
| ETON | 2.41 (0.30, 19.63) | 1.26 (0.16, 9.76) | 1.20 (0.52, 2.78) | 0.60 (0.08, 4.43) | 0.86 (0.27, 2.79) |

Estimates from Cox proportional hazards models. All models adjusted for age, site, year of entry into study. ATE and ischemic stroke models are further adjusted for hypertension, hyperlipidemia, and diabetes.